2279.HK

Hair transplant specialist Yonghe Medical Group Co. Ltd. (2279.HK) said on Tuesday it expects its net loss for 2024 to narrow significantly to 246 million yuan ($33.73 million) or less, down 55% from a 547 million yuan loss in 2023.

The company credited the improvement primarily to optimization of its store network, including the closure of underperforming outlets to focus on its best locations, leading to a substantial improvement in operational efficiency. Implementation of the company’s self-developed Hefan medical management system also enabled refined multi-process management, helping to boost its 2024 gross profit by 7% to 10% and gross profit margin by 3 percentage points to 5 percentage points compared to 2023.

Additionally, the company’s cost control measures, including adjustments to its marketing strategy and workforce optimization, led to year-on-year decreases of 8% to 9% in the ratio of sales and marketing expenses to total revenue, and 5% to 6% in the general and administrative expense ratio.

Yonghe Medical’s stock fell in the morning session on Tuesday, closing at HKD1 by midday break, down 2.9%.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…